Literature DB >> 7921603

The effect of cyclic AMP elevating agents on bradykinin- and carbachol-induced signal transduction in canine cultured tracheal smooth muscle cells.

C M Yang1, H C Hsia, S F Luo, J T Hsieh, R Ong.   

Abstract

1. The effects of cholera toxin (CTX), forskolin and dibutyryl cyclic AMP on bradykinin (BK)- and carbachol-induced accumulation of inositol phosphates (IPs) and Ca2+ mobilization were investigated in canine cultured tracheal smooth muscle cells (TSMCs). The BK-induced responses were mediated via a G protein which was not inhibited by CTX or pertussis toxin treatment. 2. BK-stimulated IPs accumulation and Ca2+ mobilization were potentiated by CTX (10 micrograms ml-1) pretreatment which was time-dependent. Maximal increase of these responses occurred after 24 h treatment with CTX. The concentration-effect relationship of BK-induced responses were shifted to the left and BK was substantially more effective in CTX-treated cells than in the control cells. This enhancing effect of CTX did not occur with carbachol. 3. Short-term (< 4 h) treatment with forskolin (10 microM) or dibutyryl cyclic AMP (1 mM) failed to accentuate BK-induced responses, but long-term (> 4 h) treatment of TSMCs with these agents mimicked the enhancing effect of CTX, suggesting that CTX-induced enhancement of BK responsiveness might be due to a rise in cyclic AMP. 4. Prolonged treatment of TSMCs with these agents was accompanied by an increase in cell surface [3H]-BK binding sites, which was inhibited by concurrent incubation with cycloheximide, an inhibitor of protein biosynthesis. Cycloheximide also abolished the potentiating actions of CTX, forskolin, and dibutyryl cyclic AMP on BK-induced IPs formation and Ca2+ mobilization. 5. The locus of this enhancement was further investigated by examining the effects of CTX, forskolin and dibutyryl cyclic AMP on A1F4(-)-induced IPs accumulation in canine TSMCs. AIF4-induced IPs accumulation was not affected by CTX, forskolin, or dibutyryl cyclic AMP treatment, supporting the contention that this stimulatory effect is located at the BK receptor level.6. These results demonstrate that the augmentation of BK-induced IPs accumulation and Ca2+mobilization produced by CTX, forskolin and dibutyryl cyclic AMP involves a cyclic AMP-dependent mechanism which is induced by a sustained increase in the level of intracellular cyclic AMP. CTX and forskolin may promote an increase of the synthesis of BK receptors, and thereby enhance BK-induced responses.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7921603      PMCID: PMC1910198          DOI: 10.1111/j.1476-5381.1994.tb13147.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  29 in total

1.  Bradykinin-activated transmembrane signals are coupled via No or Ni to production of inositol 1,4,5-trisphosphate, a second messenger in NG108-15 neuroblastoma-glioma hybrid cells.

Authors:  H Higashida; R A Streaty; W Klee; M Nirenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

2.  A new generation of Ca2+ indicators with greatly improved fluorescence properties.

Authors:  G Grynkiewicz; M Poenie; R Y Tsien
Journal:  J Biol Chem       Date:  1985-03-25       Impact factor: 5.157

3.  Phosphatidic acid may stimulate membrane receptors mediating adenylate cyclase inhibition and phospholipid breakdown in 3T3 fibroblasts.

Authors:  T Murayama; M Ui
Journal:  J Biol Chem       Date:  1987-04-25       Impact factor: 5.157

4.  Cholera toxin inhibits the T-cell antigen receptor-mediated increases in inositol trisphosphate and cytoplasmic free calcium.

Authors:  J B Imboden; D M Shoback; G Pattison; J D Stobo
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

5.  Influence of bacterial toxins and forskolin upon vasopressin-induced inositol phosphate accumulation in WRK 1 cells.

Authors:  G Guillon; M N Balestre; C Lombard; F Rassendren; C J Kirk
Journal:  Biochem J       Date:  1989-06-15       Impact factor: 3.857

6.  Detection of tissue kallikrein in the bronchoalveolar lavage fluid of asthmatic subjects.

Authors:  S C Christiansen; D Proud; C G Cochrane
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

7.  Dissociation of bradykinin-induced prostaglandin formation from phosphatidylinositol turnover in Swiss 3T3 fibroblasts: evidence for G protein regulation of phospholipase A2.

Authors:  R M Burch; J Axelrod
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

8.  Bradykinin stimulation of inositol polyphosphate production in porcine aortic endothelial cells.

Authors:  T L Lambert; R S Kent; A R Whorton
Journal:  J Biol Chem       Date:  1986-11-15       Impact factor: 5.157

9.  Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides.

Authors:  M J Berridge; R M Dawson; C P Downes; J P Heslop; R F Irvine
Journal:  Biochem J       Date:  1983-05-15       Impact factor: 3.857

10.  A smooth muscle-specific monoclonal antibody recognizes smooth muscle actin isozymes.

Authors:  A M Gown; A M Vogel; D Gordon; P L Lu
Journal:  J Cell Biol       Date:  1985-03       Impact factor: 10.539

View more
  4 in total

1.  Pharmacological and functional characterization of bradykinin receptors in canine cultured tracheal epithelial cells.

Authors:  S F Luo; C T Tsai; W B Wu; S L Pan; Y J Tsai; C M Yang
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

2.  Pharmacological characterization of bradykinin receptors in canine cultured tracheal smooth muscle cells.

Authors:  C M Yang; S F Luo; H C Hsia
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

3.  Ca2+ increase and Ca(2+)-influx in human tracheal smooth muscle cells: role of Ca2+ pools controlled by sarco-endoplasmic reticulum Ca(2+)-ATPase 2 isoform.

Authors:  Y Amrani; C Magnier; J Enouf; F Wuytack; C Bronner
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

Review 4.  The pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder disease.

Authors:  Philippa R Dale; Hana Cernecka; Martina Schmidt; Mark R Dowling; Steven J Charlton; Michael P Pieper; Martin C Michel
Journal:  Curr Opin Pharmacol       Date:  2014-03-27       Impact factor: 5.547

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.